Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.480.02%
QQQ
714.89-
BTC/USD
77161.230.0604%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Healthpeak Properties Inc

DOCNYSE
Trade with Public
Trade with Public
$20.30
-0.07-0.34%
At close: Sep 11, 5:00 PM EST
Dividend: The dividend Ex-Date is tomorrow
OverviewNewsEarnings ForecastPrice TargetsFinancialsSentimentOwnershipDividendsCompareStock Report

Healthpeak Properties Analyst Price Targets

Wall Street analyst price targets and consensus rating for Healthpeak Properties (DOC).

Price Target Range — 12 Quarters

Analyst Consensus — 19 Analysts

8Buy
11Hold
Consensus RatingOutperform# Analysts19Avg. Consensus PT$21Upside to Avg. PT+4.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 31, 2026BarclaysRichard HightowerPT RaiseEqual-Weight$23→$24
Aug 13, 2026BairdAmanda SweitzerPT RaiseOutperform$21→$24
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Equal-Weight on Healthpeak Properties, Raises Price Target to $24

Barclays analyst Richard Hightower maintains Healthpeak Properties (NYSE:DOC) with a Equal-Weight and raises the price target from $23 to $24.
Benzinga Newsdesk

Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields

In uncertain markets, investors turn to dividend-yielding stocks. Benzinga provides latest analyst ratings & news for high-yielding stocks.
Avi Kapoor

PRO
Baird Maintains Outperform on Healthpeak Properties, Raises Price Target to $24

Baird analyst Amanda Sweitzer maintains Healthpeak Properties (NYSE:DOC) with a Outperform and raises the price target from $21 to $24.
Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Healthpeak Properties, Raises Price Target to $22

Citigroup analyst Nick Joseph maintains Healthpeak Properties (NYSE:DOC) with a Neutral and raises the price target from $20 to $22.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Healthpeak Properties, Raises Price Target to $24

RBC Capital analyst Michael Carroll maintains Healthpeak Properties (NYSE:DOC) with a Outperform and raises the price target from $21 to $24.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Neutral on Healthpeak Properties, Raises Price Target to $23

Cantor Fitzgerald analyst Richard Anderson maintains Healthpeak Properties (NYSE:DOC) with a Neutral and raises the price target from $20 to $23.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved